
|Articles|September 1, 2001
- Pharmaceutical Executive-09-01-2001
- Volume 0
- Issue 0
Profits and Promotion Under Attack
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
Advertisement
Articles in this issue
almost 25 years ago
New Playing Fieldsalmost 25 years ago
Inefficiencies: Cutting Through the Junglealmost 25 years ago
Legislation: EC Proposes Changesalmost 25 years ago
Flexing Their Budgets: Big Pharma Spend Trendsalmost 25 years ago
Media Mix Town Meeting 2001: Much Ado About MediaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
The New Healthy Aging Imperative and What It Means for Pharma
4
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
5




